Kalijn F Bol1, Hanneke W Mensink2, Erik H J G Aarntzen1, Gerty Schreibelt3, Jan E E Keunen4, Pierre G Coulie5, Annelies de Klein6, Cornelis J A Punt7, Dion Paridaens8, Carl G Figdor3, I Jolanda M de Vries9. 1. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands. 2. Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands; Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands. 3. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands. 4. Department of Ophthalmology, Radboud University Medical Centre, Nijmegen, the Netherlands. 5. De Duve Institute, Université Catholique de Louvain, Brussels, Belgium. 6. Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands. 7. Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands. 8. Department of Ophthalmology, Rotterdam Eye Hospital, Rotterdam, the Netherlands. 9. Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands. Electronic address: J.deVries@ncmls.ru.nl.
Abstract
PURPOSE: To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma. DESIGN: Interventional case series. METHODS: We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. RESULTS: Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. CONCLUSIONS:Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma.
RCT Entities:
PURPOSE: To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma. DESIGN: Interventional case series. METHODS: We analyzed 14 patients with metastatic uveal melanoma treated with dendritic cell vaccination. Patients with metastatic uveal melanoma received at least 3 vaccinations with autologous dendritic cells, professional antigen-presenting cells loaded with melanoma antigens gp100 and tyrosinase. The main outcome measures were safety, immunologic response, and overall survival. RESULTS: Tumor-specific immune responses were induced with dendritic cell vaccination in 4 (29%) of 14 patients. Dendritic cell-vaccinated patients showed a median overall survival with metastatic disease of 19.2 months, relatively long compared with that reported in the literature. No severe treatment-related toxicities (common toxicity criteria grade 3 or 4) were observed. CONCLUSIONS: Dendritic cell vaccination is feasible and safe in metastatic uveal melanoma. Dendritic cell-based immunotherapy is potent to enhance the host's antitumor immunity against uveal melanoma in approximately one third of patients. Compared with other prospective studies with similar inclusion criteria, dendritic cell vaccination may be associated with longer than average overall survival in patients with metastatic uveal melanoma.
Authors: Anja Wessely; Theresa Steeb; Michael Erdmann; Lucie Heinzerling; Julio Vera; Max Schlaak; Carola Berking; Markus Vincent Heppt Journal: Int J Mol Sci Date: 2020-01-29 Impact factor: 5.923